Advertisement

Control of Blood Pressure in Hypertensive Neurological Emergencies

  • Lisa Manning
  • Thompson G. Robinson
  • Craig S. AndersonEmail author
Hypertensive Emergencies (BM Baumann, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Hypertensive Emergencies

Abstract

Neurological hypertensive emergencies cause significant morbidity and mortality. Most occur in the setting of ischaemic stroke, spontaneous intracerebral hemorrhage (ICH), or subarachnoid hemorrhage (SAH), but other causes relate to hypertensive encephalopathy and reversible cerebral vasoconstriction syndrome (RCVS). Prompt and controlled reduction of blood pressure (BP) is necessary, although there remains uncertainty as to the optimal rate of decline and ideal antihypertensive agent. There is probably no single treatment strategy that covers all neurological hypertensive emergencies. Prompt diagnosis of the underlying disorder, recognition of its severity, and appropriate targeted treatment are required. Lack of comparative-effectiveness data leaves clinicians with limited evidence-based guidance in management, although significant developments have occurred recently in the field. In this article, we review the management of specific neurological hypertensive emergencies, with particular emphasis on recent evidence.

Keywords

Hypertension Emergencies Critical care Neurological Subarachnoid hemorrhage Stroke Intracerebral hemorrhage Encephalopathy 

Notes

Compliance with Ethics Guidelines

Conflict of Interest Lisa Manning declares that she has no conflict of interest.

Thompson G. Robinson has received grants from ANHMRC Heath Foundation/The Stroke Association (Grant Funding for INTERACT2 Grant Funding for COSSACS) and The Stroke Association NIHR British Heart Foundation. He has also received advisory board consultancy fees and payments for lectures from Boehringer Ingelhelm. Dr. Robinson has also received paid travel accommodations from Boehringer Ingelhelm, Educational Grant to attend European Stroke Conference).

Craig S. Anderson has received a research fellowship grant from the National Health & Medical Research Council of Australia.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.PubMedGoogle Scholar
  2. 2.•
    Peacock IV WF, Hilleman DE, Levy PD, Rhoney DH, Varon J. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med. 2012;30(6):981–93. A recent systematic review of treatment in hypertensive crises. The results of this review show comparable efficacy and safety for nicardipine and labetalol, although nicardipine appears to provide more predictable and consistent BP control than labetalol. In a number of included studies there was a theme of a relative lack of awareness among health care professionals regarding the use of nicardipine in patients with stroke, despite its inclusion in AHA/ASA guidelines, and authors suggest a requirement for education regarding the appropriate use and the approved indications of the drug. PubMedGoogle Scholar
  3. 3.
    Papadopoulus D, Lordanis M, Thomopoulos C, Makris T, et al. Hypertension crisis. Blood Press. 2010;19:328–36.Google Scholar
  4. 4.
    Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P. Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hypertension. 1996;27(1):144–7.PubMedGoogle Scholar
  5. 5.
    Martin JFV, Higashiama E, Garcia E, et al. Hypertensive crisis profile. Prevelence and clinical presentation. Arq Bras Cardiol. 2004;83:131–6.PubMedGoogle Scholar
  6. 6.
    Bennett NM, Shea S. Hypertensive emergency: case criteria, sociodemographic profile and previous care of 100 cases. Am J Public Health. 1988;78:636–40.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Varon J. Treatment of acute hypertension: current and newer agents. Drugs. 2008;68:283–97.PubMedGoogle Scholar
  8. 8.
    Mancia G, Fagard R, Narkiewicz K, et al. 2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC task force for the management of arterial hypertension. J Hypertens. 2013;31(10):1925–38.Google Scholar
  9. 9.
    Paulson OB, Strandgaard S, Edvinson L. Cerebral autoregulation. Cerebrovasc Brain Metab Rev. 1990;2:161–92.PubMedGoogle Scholar
  10. 10.
    Symon L, Held K, Dorsch NWC. A study of regional autoregulation in the cerebral circulation to increased perfusion pressure in normocapnia and hypercapnia. Stroke. 1973;4(2):139–47.PubMedGoogle Scholar
  11. 11.
    Rose JC, Mayer SA. Optimizing blood pressure in neurologic emergencies. Neurocrit Care. 2004;1:287–99.PubMedGoogle Scholar
  12. 12.
    Dawson SL, Panerai R, Potter J. Serial changes in static and dynamic cerebral autoregulation after acute ischaemic stroke. Cerebrovasc Dis. 2003;16:69–75.PubMedGoogle Scholar
  13. 13.
    Aries MJH, Elting JW, De Keyser J, Kremer BPH, Vroomen PCAJ. Cerebral autoregulation in stroke: a review of transcranial doppler studies. Stroke. 2010;41(11):2697–704.PubMedGoogle Scholar
  14. 14.
    Yamamoto S, Nishizawa S, Tsukada H, et al. Cerebral blood flow autoregulation following subarachnoid hemorrhage in rats: chronic vasospasm shifts the upper and lower limits of the autoregulatory range toward higher blood pressures. Brain Res. 1998;782(1–2):194–201.PubMedGoogle Scholar
  15. 15.
    Strangaard S, Paulson OB. Cerebral blood flow and its pathophysiology in hypertension. Am J Hypertens. 1989;6:486–92.Google Scholar
  16. 16.
    Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation. 2008;118(2):176–87.PubMedGoogle Scholar
  17. 17.
    Morgenstern LB, Hemphill JC, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41(9):2108–29.PubMedPubMedCentralGoogle Scholar
  18. 18.
    The Brain Trauma Foundation. Guidelines for cerebral perfusion pressure. J Neurotrauma. 2000;17:507–11.Google Scholar
  19. 19.
    Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of diseases study 2010. Lancet. 2012;380(9859):2095–128.PubMedGoogle Scholar
  20. 20.
    International Stroke Trial Collaborative Group. The international stroke trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet. 1997;349(9065):1569–81.Google Scholar
  21. 21.
    Qureshi AI, Ezzeddine MA, Nasar A, Suri MF, Kirmani JF, Hussein HM. Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States. Am J Emerg Med. 2007;25:32–8.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis. Retrospective analysis from safe implementation of thrombolysis in stroke-international stroke thrombolysis register (SITS-ISTR). Stroke. 2009;40:2442–9.PubMedGoogle Scholar
  23. 23.
    Robinson T. The predictive role of 24-hour compared to casual blood pressure levels on outcome following acute stroke. Cerebrovasc Dis. 1997;7:264–72.Google Scholar
  24. 24.
    Dawson SL, Manktelow BN, Robinson TG, Panerai RB, Potter JF. Which parameters of beat-to-beat blood pressure and variability best predict early outcome after acute ischemic stroke? Stroke. 2000;31(2):463–8.PubMedGoogle Scholar
  25. 25.
    Ahmed N, Wahlgren N. High initial blood pressure after acute stroke is associated with poor functional outcome. J Intern Med. 2001;249:467–73.PubMedGoogle Scholar
  26. 26.
    Leonardi-Bee J, Bath PMW, Phillips SJ, Sandercock PAG, for the IST Collaborative Group. Blood pressure and clinical outcomes in the international stroke trial. Stroke. 2002;33(5):1315–20.PubMedGoogle Scholar
  27. 27.
    Aslanyan S, Fazekas F, Weir CJ, Horner S, Lees KR. GAIN international steering committee and investigators. Effect of blood pressure during the acute period of ischemic stroke on stroke outcome: a tertiary analysis of the GAIN international trial. Stroke. 2003;34:2420–5.PubMedGoogle Scholar
  28. 28.
    Aslanyan S, Weir CJ, Lees KR, GAIN International Steering Committee and Investigators. Elevated pulse pressure during the acute period of ischemic stroke is associated with poor stroke outcome. Stroke. 2004;33:153–5.Google Scholar
  29. 29.
    Jensen MB, Yoo B, Clarke WR, Davis PH, Adams Jr HR. Blood pressure as an independent prognostic factor in acute ischemic stroke. Can J Neurol Sci. 2006;33:34–8.PubMedGoogle Scholar
  30. 30.
    Okumura K, Ohya Y, Maehara A, Wakugami K, Iseki K, Takishita S. Effects of blood pressure levels on case fatality after acute stroke. J Hypertens. 2005;23:1217–23.PubMedGoogle Scholar
  31. 31.•
    Sandset EC, Bath PM, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011;377(9767):741–50. 2029 patients with acute stroke and SBP > 140mmHg were allocated to candesartan or placebo. In contrast to other recent trials (CHIPPS), there was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure. If anything, the evidence suggested a harmful effect. PubMedGoogle Scholar
  32. 32.
    Robinson TG, Potter JF, Ford GA, et al. Effects of antihypertensive treatment after acute stroke in the continue or stop post-stroke antihypertensives collaborative study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol. 2010;9(8):767–75.PubMedGoogle Scholar
  33. 33.
    Potter JF, Robinson TG, Ford GA, et al. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol. 2009;8(1):48–56.PubMedGoogle Scholar
  34. 34.
    Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for treatment of acute lacunar stroke syndromes. Lancet. 2004;363:439–45.Google Scholar
  35. 35.
    Wahlgren NG, MacMahon DG, De Keyser J, Indredavik B, Ryman T. Intravenous Nimodipine west European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis. 1994;4:204–10.Google Scholar
  36. 36.
    Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JR. Low dose beta blockade in acute stroke ("BEST" trial): an evaluation. Br Med J. 1988;296:737–41.Google Scholar
  37. 37.•
    He J, Zhang Y, Xu T, et al, for the CATIS investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischaemic stroke. JAMA. 2014;311(5):479–489. doi: https://doi.org/10.1001/jama.2013.282543. The most recently published large trial of blood pressure reduction in ischemic stroke, in which 4071 patients with acute stroke and elevated SBP were randomized to antihypertensive treatment (with the aim of lowering SBP by 10 to 25% in 24 hours), or to discontinue all antihypertensive medications. BP reduction did not reduce the likelihood of death or major disability at 14 days. PubMedGoogle Scholar
  38. 38.
    Schrader J, Lüders S, Kulschewski A, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003;34(7):1699–703.PubMedGoogle Scholar
  39. 39.
    Bath PMW, Martin RH, Palesch Y, et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke. 2009;40(11):3541–6.PubMedGoogle Scholar
  40. 40.
    Astrid G, Hornslien M, on Behalf of the Scandinavian Candesartan Acute Stroke Trial Study Group, et al. Effects of candesartan in acute stroke on cognitive function and quality of life: results from the scandinavian candesartan acute stroke trial. Stroke. 2013;44:2022–4.Google Scholar
  41. 41.
    Bath PMW. Efficacy of nitric oxide in stroke (ENOS) trial: summary of protocol (version 1.5). https://doi.org/www.enos.ac.uk/enossummaryv15.htm. Updated 2007. Accessed 21 October 2013.
  42. 42.
    Geeganage C, Bath PMW. Vasoactive drugs for acute stroke. Cochrane Database of Systematic Reviews 2010, Issue 7. Art. No.: CD002839. doi: https://doi.org/10.1002/14651858.CD002839.pub2.
  43. 43.
    Lawes CMM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke. 2004;35(3):776–85.PubMedGoogle Scholar
  44. 44.
    The Blood Pressure in Acute Stroke Collaboration. Vasoactive drugs for acute stroke. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD002839. doi: https://doi.org/10.1002/14651858.CD002839.
  45. 45.
    Bath P. International society of hypertension (ISH): statement on the management of blood pressure in acute stroke. J Hypertens. 2003;21:665–72.PubMedGoogle Scholar
  46. 46.
    Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association stroke council, clinical cardiology council, cardiovascular radiology and intervention council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: the American academy of neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 2007;115(20):e478–534.PubMedGoogle Scholar
  47. 47.
    Jauch EC, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870–947.PubMedGoogle Scholar
  48. 48.
    Anderson C. Enhanced control of hypertension and thrombolysis stroke study (ENCHANTED). https://doi.org/clinicaltrials.gov/show/NCT01422616. Updated 2013. Accessed 21 October 2013.
  49. 49.
    Saposnik G, Del Brutto OH, for the Iberoamerican Society of Cerebrovascular Diseases. Stroke in south America: a systematic review of incidence, prevalence, and stroke subtypes. Stroke. 2003;34(9):2103–7.PubMedGoogle Scholar
  50. 50.
    Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003;2(1):43–53.PubMedGoogle Scholar
  51. 51.
    Zhang Y, Reilly K, Tong W, et al. Blood pressure and clinical outcome among patients with acute stroke in Inner Mongolia, China. J Hypertens. 2008;26:1446–52.PubMedGoogle Scholar
  52. 52.
    Ohwaki K, Yano E, Nagashima H, Hirata M, Nakagomi T, Tamura A. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke. 2004;35(6):1364–7.PubMedGoogle Scholar
  53. 53.
    Robinson TG, Potter JF. Blood pressure in acute stroke. Age Ageing. 2004;33(1):6–12.PubMedGoogle Scholar
  54. 54.
    Rodriguez-Luna D, Piñeiro S, Rubiera M, et al. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. Eur J Neurol. 2013;20(9):1277–83.PubMedGoogle Scholar
  55. 55.
    Jauch EC, Lindsell CJ, Adeoye O, Khoury J, Barsan W, Broderick J. Lack of evidence for an association between hemodynamic variables and hematoma growth in spontaneous intracerebral hemorrhage. Stroke. 2006;37:2061.PubMedGoogle Scholar
  56. 56.
    Butcher KS, Jeerakathil T, Hill M, et al. The intracerebral haemorrhage acutely decreasing arterial pressure trial. Stroke. 2013;44:620–626.PubMedGoogle Scholar
  57. 57.
    Willmot M, Leonardi-Bee J, Bath PMW. High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension. 2004;43(1):18–24.PubMedGoogle Scholar
  58. 58.
    Vemmos KN, Tsivgoulis G, Spengos K, Zakopoulos N, Synetos A. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. J Intern Med. 2004;255:257–65.PubMedGoogle Scholar
  59. 59.
    Intercollegiate Stroke Working Party. National clinical guideline for stroke. 4th ed. London: Royal College of Physicians; 2012.Google Scholar
  60. 60.••
    Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355–65. This large trial of intensive BP lowering versus standard guideline care in patients with acute ICH and elevated SBP, showed borderline significant reduction in poor outcome at 90-days, defined by death or major disability, with a significant favorable shift in an ordinal analysis of the distribution of scores on the modified Rankin Scale in the intensive treatment group. Furthermore, intensive BP reduction was shown to be safe and to result in significantly better health-related quality of life. Effects were consistant across different patient and disease characteristics. PubMedGoogle Scholar
  61. 61.
    Qureshi A. Antihypertensive treatment of acute cerebral hemorrhage (ATACH): rationale and design. Neurocrit Care. 2007;6:56–66.PubMedGoogle Scholar
  62. 62.
    Powers WJ, Zazulia AR, Videen TO, Adams RE, Yundt KD, Aiyagari V. Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage. Neurology. 2001;57:18–24.PubMedGoogle Scholar
  63. 63.
    Qureshi AI, Mohammad YM, Yahia AM, Suarez JI, Siddiqui AM. A prospective multicenter study to evaluate the feasibility and safety of aggressive antihypertensive treatment in patients with acute intracerebral hemorrhage. J Intensive Care Med. 2005;20:44–52.Google Scholar
  64. 64.
    Qureshi AI, Bliwise DL, Bliwise NG, Akbar MS, Uzen G, Frankel MR. Rate of 24-hour blood pressure decline and mortality after spontaneous intracerebral hemorrhage: a retrospective analysis with a random effects regression model. Crit Care Med. 1999;27:480–5.PubMedGoogle Scholar
  65. 65.
    Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008;7(5):391–9.PubMedGoogle Scholar
  66. 66.
    Vaughan C, Delanty N. Hypertensive emergencies. Lancet. 2000;356:411–7.PubMedGoogle Scholar
  67. 67.
    Hinchey J, Chaves C, Appignani B. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1999;52:1497–500.Google Scholar
  68. 68.
    Pearce C, Wallin J. Labetalol and other agents that block both alpha and beta adrenergic receptors. Cleve Clin J Med. 1994;61:59–69.PubMedGoogle Scholar
  69. 69.
    Rose J, Mayer S. Optimising blood pressure in neurological emergencies. Neurocrit Care. 2004;1:287–99.PubMedGoogle Scholar
  70. 70.
    Neutel J, Smith D, Wallin D, et al. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. Am J Hypertens. 1994;7:623–8.PubMedGoogle Scholar
  71. 71.
    Steiner T et al. European stroke organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35:93–112.PubMedGoogle Scholar
  72. 72.
    King Jr JT. Epidemiology of aneurysmal subarachnoid hemorrhage. Neuroimaging Clin N Am. 1997;7:659–68.PubMedGoogle Scholar
  73. 73.
    Hop J, Rinkel GJ, et al. Case fatality rates and functional outcome after sud-arachnoid haemorrhage: a systematic review. Stroke. 1997;28:660–4.PubMedGoogle Scholar
  74. 74.
    Qureshi AI, Suri MF, Yahia AM, Suarez JI, Guterman LR, Hopkins LN. Risk factors for subarachnoid hemorrhage. Neurosurgery. 2001;49:607–12.PubMedGoogle Scholar
  75. 75.
    Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL. Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2007;38(8):2315–21.PubMedGoogle Scholar
  76. 76.
    Gomis P, Rousseaux P, Johy D, et al. Initial prognostic factors of aneurysmal subarachnoid haemorrhage. Neurochirurgie. 1994;40:18–30.PubMedGoogle Scholar
  77. 77.
    Duran L, Balci K, et al. Has admission blood pressure any prognostic value in patients with subarachnoid haemorrhage: an emergency department experience. J Clin Hypertens. 2013;15:737–41.Google Scholar
  78. 78.
    Wartenberg KE. Update on the management of subarachnoid hemorrhage. https://doi.org/www.medscape.com/viewarticle/780438_3. Updated 2013. Accessed 21 October 2013.
  79. 79.
    Wijdicks EFM, Vermeulen M, Murray GD, Hijdra A, van Gijn J. The effects of treating hypertension following aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 1990;92(2):111–7.PubMedGoogle Scholar
  80. 80.
    Ohkuma H, Tsurutani H, Suzuki S. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. Stroke. 2001;32(5):1176–80.PubMedGoogle Scholar
  81. 81.
    Naidech AM, Janjua N, Kreiter KT, et al. Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. Arch Neurol. 2005;62(3):410–6.PubMedGoogle Scholar
  82. 82.
    Fujii Y et al. Ultra early rebleeding in sub arachnoid haemorrhage. J Neurosurg. 1996;84:35–42.PubMedGoogle Scholar
  83. 83.
    Budohoski KP, Czosnyka M, Kirkpatrick PJ, Smielewski P, Steiner LA, Pickard JD. Clinical relevance of cerebral autoregulation following subarachnoid haemorrhage. Nat Rev Neurol. 2013;9:152–63.PubMedGoogle Scholar
  84. 84.
    Adams HP. Early management of aneurysmal subarachnoid hemorrhage: a report of the cooperative aneurysm study. J Neurosurg. 1981;54:141–5.PubMedGoogle Scholar
  85. 85.
    Tomer JC, Nibbelink DW, Burmeister LF. Statistical comparisons of end results of a randomized treatment study. In: Sans AL, Nibbelink DW, Tomer JC, editors. Aneurysmal subarachnoid hemorrhage: report of the cooperative study. Baltimore, Md: Urban & Schwarzenberg; 1981. p. 249–276.Google Scholar
  86. 86.
    Hasan D, Vermeulen M, Wijdicks EF, Hijdra A, van Gijn J. Effect of fluid intake and antihypertensive treatment on cerebral ischemia after subarachnoid hemorrhage. Stroke. 1989;20(11):1511–5.PubMedGoogle Scholar
  87. 87.
    Bederson JB, Connolly Jr ES, Batjer HHM, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the stroke council, American Heart Association. Stroke. 2009;40(3):994–1025.PubMedGoogle Scholar
  88. 88.
    Ducros A, Boukobza M, Porcher R, et al. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain. 2007;130:3091–101.PubMedGoogle Scholar
  89. 89.
    Lu S, Liao Y, Fu JL, et al. Nimodipne for treatment of primary thunderclap headache. Neurology. 2004;62:1414–6.PubMedGoogle Scholar
  90. 90.
    Chen SP, Fuh JL, Wang S. Reversible cerebral vaoconstriction syndrome: an under-recognised clinical emergency. Neurol Disord. 2010;3(3):161–71.Google Scholar
  91. 91.
    Bouchard M, Verreault S, et al. Intra-arterial milrinone for reversible cerebral vasoconstrictor syndrome. Headache. 2009;49:142–5.PubMedGoogle Scholar
  92. 92.
    Lund-Johansen P. Pharmacology of combined alpha and beta blockade. Haemodynamic effects of labetalol. Drugs. 1984;28:35–50.PubMedGoogle Scholar
  93. 93.
    Olsen K, Svendsen L, Lasen F, Paulson O. Effect of labetalol of cerebral blood flow, oxygen metabolism and autoregulation in healthy humans. Br J Anaesth. 1995;75:51–4.PubMedGoogle Scholar
  94. 94.
    Marek P, Varon J. Hypertensive crises: challenges and management. Chest. 2007;131:1949–62.Google Scholar
  95. 95.
    Lui-DeRyke X, Janisse J, Coplin W, et al. A comparison of nicardipine and labetalol for acute hypertension management following acute stroke. Neurocrit Care. 2008;9:167–76.Google Scholar
  96. 96.
    Lui-DeRyke X, Parker Jnr D, Levy P, et al. A prospective evaluation of labetalol versus nicardipine for acute hypertension management following stroke. Crit Care Med. 2009;37(suppl):161.Google Scholar
  97. 97.
    Malesker M, Kondrack R, et al. Nicardipine in the management of hypertension in critically ill patients. Chest. 2009;136(No.4_MeetingAbstracts):43S. doi: https://doi.org/10.1378/chest.136.4_MeetingAbstracts.43S-a.Google Scholar
  98. 98.
    Freiderich J, Butterworth J. Sodium nitroprusside: twenty years and counting. Anaesth Analg. 1995;81:152–62.Google Scholar
  99. 99.
    Rodrigues G, Varon J. A unique agent for the critical care practitioner: clevidipine. Crit Care Shock. 2006;9:37–41.Google Scholar
  100. 100.
    Pollock C, Varon J, et al. Clevidipine is safe and effective for treatment of patients with acute severe hypertension. Ann Emerg Med. 2009;53:329–38.Google Scholar
  101. 101.
    Aronson S, Dyke C, et al. The ECLIPSE trials: comparitive studies of clevidipine to nitroglycerine, sodium nitroprusside and nicardipine for treatment of acute hypertension in cardiac surgery patients. Anaesth Analg. 2008;107:1110–21.Google Scholar
  102. 102.•
    Graffagnino C, Bergese S, Love J, Schneider D, et al. Clevidipine rapidly and safely reduces blood pressure in acute intracerebral haemorrhage: the ACCELERATE trial. Cerebrovasc Dis. 2013;36(173):180. This pilot study is the first to evaluate the safety and efficacy of clevidipine for rapid BP control in ICH. Clevidipine was effective and safe. Furthermore, patients showed minimal haematoma expansion which may warrant further investigation, particularly given ongoing uncertainty surrounding the effect of BP on hematoma growth in ICH. Google Scholar
  103. 103.
    Bath PMW, Wilmot M, et al. Nitric oxide donors, L arginine or nitric oxide synthase inhibitors for acute stroke. Cochrane Database Syst Rev. 2002;4, CD001928.Google Scholar
  104. 104.
    Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies. A systematic review of the literature. J Gen Intern Med. 2002;17(12):937–45.PubMedPubMedCentralGoogle Scholar
  105. 105.
    Hirschl MM, Binder M, Bur A, Herkner H, Müllner M, Woisetschläger C, et al. Safety and efficacy of urapidil and sodium nitroprusside in the treatment of hypertensive emergencies. Intensive Care Med. 1997;23(8):885–8.PubMedGoogle Scholar
  106. 106.
    Buch J. Urapidil, a dual-acting antihypertensive agent: current usage considerations. Adv Ther. 2010;27(7):426–33.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Lisa Manning
    • 1
  • Thompson G. Robinson
    • 1
  • Craig S. Anderson
    • 2
    Email author
  1. 1.Department of Cardiovascular Sciences and NIHR Biomedical Research Unit in Cardiovascular DiseaseUniversity of LeicesterLeicesterUK
  2. 2.The George Institute for Global HealthUniversity of Sydney and Royal Prince Alfred HospitalSydneyAustralia

Personalised recommendations